The side effects of immunotherapies for cancer can affect any body system—both during active treatment and long after treatment has ended—and ongoing education is needed for oncologists, patients, primary care providers, and other clinicians caring for patients post-treatment. On this episode of CANCER BUZZ, learn about the transition from immunotherapy into post-treatment survivorship, how it differs from chemotherapy, and why coordination and communication among providers, patients, and caregivers is essential.

Guest:

Regina Jacob, MD, MSCE, Assistant Professor, Section of General Internal Medicine, Lewis Katz School of Medicine at Temple University

Related Content:

• “Managing Survivorship Care After Immunotherapy,” by Regina Jacob, MD, MSCE

• Planning for Survivorship After Checkpoint Inhibitors (webinar)

• Real-World Experiences in Immunotherapy Delivery, in the July/August 2017 issue of Oncology Issues

• "Moving Beyond Silos: Involving Non-Oncology Specialists in IO," by the ACCC Immuno-Oncology Institute

• Elevating Survivorship: Results from Two National Surveys, by the ACCC Immuno-Oncology Institute

The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Community Cancer Centers.